This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Sep 2020

Novel customizable and flexible single-use assembly solution

Hugh Purity New England's solution can utilize other vendors' components and can be implemented directly into any process.

Demand for single-use assembly solutions in the biopharma industry continues to increase, with the market expected to be worth $26.89 billion by 2025.

To help meet that demand, High Purity New England (HPNE), a supplier of biopharma equipment and process solutions for the biopharma industry, has created HPConnexx, a single-use assembly solution suitable for all areas of biopharmaceutical processing from discovery to fill-finish.

Manufactured in an ISO 7 Cleanroom, the solution can utilize other vendors' components and can be implemented directly into any process.

“The solution, and the support we deliver around it, is truly unique as it can be customized in any way the customer requires. It can be connected to any existing process at any scale and utilize any components regardless of inter-company connectivity," explained the company's CEO and founder, Mark Sitcoske.

There is no minimum order size for an assembly and lead times can be as short as weeks, compared with the industry standard of months.

The team at HPNE also provide full integrity and validation testing on its single-use assemblies.

Sitcoske added: “Single-use technologies can reduce the costs associated with infrastructure, save time by decreasing the need for cleaning and validation and negate the risk of cross contamination. However, not all single-use solutions are fully customizable, and many have lengthy lead times for installation. That is why we developed HPConnexx.”

Related categories
Biopharmaceutical Products

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.